COMMUNIQUÉS West-GlobeNewswire

Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial

13/11/2017 - 14:30

NORCROSS, Ga., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute today announced the [...]

BriaCell Announces Advancement of its Small Molecule Program and Patent Allowance

13/11/2017 - 14:30

BERKELEY, Calif. and VANCOUVER, British Columbia, Nov. 13, 2017 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V: BCT ) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company [...]

SteadyMed Reports Third Quarter 2017 Financial Results and Provides Corporate Update

13/11/2017 - 14:30

SAN RAMON, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq: STDY ), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with [...]

80% of Prostate Cancer Patients in OncBioMune Phase 1 Clinical Trial of ProscaVax Show No Disease Progression at the First Post-Therapy Follow-up

13/11/2017 - 14:25

BATON ROUGE, La., Nov. 13, 2017 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of a proprietary [...]

Peregrine Announces Date of 2017 Annual Meeting of Stockholders

13/11/2017 - 14:05

TUSTIN, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM ) (NASDAQ: PPHMP ) today announced that its 2017 Annual Meeting of Stockholders will be held on January 18, 2018, at 14191 [...]

Nexstim gains FDA clearance to commercialise its NBT® system in the US for the treatment of depression

13/11/2017 - 14:02

C ompany announcement, Helsinki, 13 November 2017 at 3 pm Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or " Company "), a medical technology company developing and marketing pioneering navigated non-invasive brain [...]

Medtronic to Present New Clinical Data on Vascular Interventions and Key Symposia at VEITHsymposium 2017

13/11/2017 - 14:01

DUBLIN - November 13, 2017 - Medtronic plc (NYSE: MDT) today announced several noteworthy presentations of clinical studies and symposia on aortic, peripheral, endoVenous, and vascular embolization therapies at the 44 [...]

Fibrocell Reports Third Quarter 2017 Financial Results and Recent Highlights

13/11/2017 - 14:00

EXTON, Pa., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC ), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today [...]

Immune Design to Present at Jefferies 2017 London Healthcare Conference

13/11/2017 - 14:00

SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ ), a clinical-stage immunotherapy company focused on cancer, today announced that Carlos Paya, M.D., Ph.D., [...]

Tyme to Present at Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference

13/11/2017 - 14:00

NEW YORK, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Tyme Inc. (Nasdaq: TYME ), a biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics, today announced that Jonathan Eckard, Chief [...]

Global Blood Therapeutics Announces Completion of Safety Review by Independent Data and Safety Monitoring Board (DSMB) for Phase 3 HOPE Study in Sickle Cell Disease

13/11/2017 - 14:00

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT ) announced today that the independent Data and Safety Monitoring Board (DSMB) for the Phase 3 HOPE ( H [...]

Clinical Genomics and Quest Diagnostics announce FDA 510(K) clearance of InSure® ONE™

13/11/2017 - 14:00

At-home collection, one-day fecal immunochemical test that meets American Cancer Society guidelines and HEDIS quality measures for lower gastrointestinal bleeding screening programs A number of medical conditions may be [...]

Intra-Cellular Therapies Expands Its Executive Team with the Appointment of Dr. Andrew Satlin as Executive Vice President and Chief Medical Officer

13/11/2017 - 14:00

NEW YORK, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI ), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced [...]

Clementia annonce ses résultats financiers et les faits saillants du troisième trimestre 2017

13/11/2017 - 14:00

Premier appel public à l’épargne achevé générant un produit net de 128,2 M$ La FDA des États-Unis accorde la désignation de traitement révolutionnaire au palovarotene contre la fibrodysplasie ossifiante progressive (FOP [...]

Clementia Reports Third Quarter 2017 Financial Results and Business Highlights

13/11/2017 - 14:00

Initial Public Offering Completed, Raising $128.2 Million in Net Proceeds U.S. FDA Grants Breakthrough Therapy Designation to Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP) On Track to Begin Pivotal MOVE [...]

Le personnel infirmier du Canada célèbre la Semaine nationale des infirmières et des infirmiers praticiens en lançant un projet visant à augmenter les soins dispensés par les IP afin de répondre aux besoins croissants

13/11/2017 - 14:00

OTTAWA, 13 nov. 2017 (GLOBE NEWSWIRE) -- Afin de célébrer la Semaine nationale des infirmières et des infirmiers praticiens (IP), qui se tiendra du 12 au 18 novembre, le personnel infirmier du Canada lance un projet de [...]

Canada’s nurses celebrate National Nurse Practitioner Week by launching a project to expand NP care to meet growing need

13/11/2017 - 14:00

OTTAWA, Nov. 13, 2017 (GLOBE NEWSWIRE) -- In celebration of National Nurse Practitioner (NP) Week taking place from November 12 to 18, Canada’s nurses are launching a retention and recruitment project aimed at [...]

Diffusion Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

13/11/2017 - 14:00

FDA Clears Phase 3 Protocol for Patient Enrollment in GBM Brain Cancer Trial “First Patient In” Expected this Year Company Charter Amendment Addresses Nasdaq Listing Issue Additions to Board and Management Strengthen [...]

CymaBay Therapeutics to Present at Three Investor Conferences

13/11/2017 - 14:00

NEWARK, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY ), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high [...]